News

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III ...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...
Fierce Pharma12h

RemeGen's telitacicept meets the mark in ph. 3 Sjögren's study in China

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

A look at Venus Williams' tennis career and comeback. She's returning to the US Open at age 45

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

NWSL’s Chicago Stars name Martin Sjögren as new head coach

Sjögren, who is currently head coach of Hammarby in Sweden’s top women’s flight, will join the club in January.

Former Norway coach Martin Sjögren named coach of the NWSL's Chicago Stars

The Chicago Stars have named former Norway women's national team coach Martin Sjögren as the National Women's Soccer League ...